Vizsgálati helyszín
Bradfordhill
Santiago, Santiago Metropolitan 8420383, ChileMég nincs intézményhez kötve
Az itteni vizsgálatok
Miről szól a helyszín 12 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis5 vizsgálat
- 1/2. fázis3 vizsgálat
- 2/3. fázis3 vizsgálat
- 2. fázis1 vizsgálat
- Állapot
- Toboroz9 vizsgálat
- Fut, nem toboroz2 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- Bristol-Myers Squibb10 vizsgálat
- Eli Lilly and Company1 vizsgálat
- Pfizer1 vizsgálat
Futó vizsgálatok
Toboroz
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764· 2. fázis· Bristol-Myers Squibb· Forrás
Contact: Carlos Rojas, Site 0149
Toboroz
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351· 1/2. fázis· Bristol-Myers Squibb· Forrás
Contact: Carlos Rojas, Site 0005
Toboroz
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Carlos Rojas, Site 0077
Toboroz
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076· 1/2. fázis· Bristol-Myers Squibb· Forrás
Contact: Carlos Rojas, Site 0064
Toboroz
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Carlos Rojas, Site 0199
Toboroz
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080· 2/3. fázis· Bristol-Myers Squibb· Forrás
Contact: Carlos Rojas, Site 0007
Fut, nem toboroz
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121· 2/3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· 2/3. fázis· Bristol-Myers Squibb· Forrás
Contact: Carlos Gallardo, Site 0018
Toboroz
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· 3. fázis· Eli Lilly and Company· Forrás
Contact: Carlos Rojas (principal investigator)
Toboroz
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT06618287· 1/2. fázis· Bristol-Myers Squibb· Forrás
Contact: Carlos Rojas, Site 0047
Toboroz
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779· 3. fázis· Pfizer· Forrás
Toboroz
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Carlos Rojas, Site 0214
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek